+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Extracellular Matrix Patches Market - Growth, Trends, Covid-19 Impact, And Forecasts (2022 - 2027)

  • PDF Icon


  • 120 Pages
  • August 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 5616736
UP TO OFF until Dec 31st 2023
The Extracellular Matrix Patches market is projected to witness a CAGR of 6.65% during the forecast period (2022 - 2027).

COVID-19 has impacted the healthcare industry. The restrictions imposed by the government across the world have impacted the treatment and surgeries of the patients. The recognition of the need to limit operative capacity to only emergent and/or urgent procedures have resulted in delayed elective cardiac and vascular procedure and surgeries. The guidelines were set forth by national surgical and specialty societies. According to the study published in the British Journal of Surgery in May 2020, "Elective surgery cancellations due to the COVID-19 pandemic: global predictive modeling to inform surgical recovery plans", based on a 12-week period of peak disruption to hospital services due to COVID-19, around 28.4 million elective surgeries worldwide were canceled or postponed in 2020. ​ More than 580,000 planned surgeries in India were canceled or delayed as a result of the COVID-19 pandemic.

The rise in prevalence of trauma, congenital heart disease, rise in prevalence of vascular diseases, increase in vascular surgeries, and a surge in the geriatric population which require reconstruction and repair procedures, are the key factors driving the growth of the market. According to the data published by Health System Tracker, 2022, it has been observed that heart disease is the number one leading cause of death in the United States. The World Heart Federation has predicted more than 23 million cardiac-related deaths per year by 2030.

One of the major elements driving the expansion of extracellular matrix patches is a growing knowledge of the advantages of biological patches over synthetic ones.

Increasing adoption of extracellular matrix in hernia and pelvic reconstruction surgeries promotes the growth of these products, and rising technological advancements have favored the market growth. For instance, Aziyo Biologics' AltiPly patch is a ready-to-use patch that does not require rehydration and is easy to handle at room temperature. It involves patented processing that boosts growth level variables and speeds up the healing process in situations of venous leg ulcers, diabetic foot ulcers, and pressure wounds.

For instance, abdominal wall hernia surgery is one of the most common procedures performed around the world. The extracellular matrix is being developed by several businesses for pelvic reconstruction and hernia surgery. For instance, Boston Scientific Corporation's Xenform Soft Tissue Repair Matrix is suggested for soft tissue regeneration, particularly in cases of pelvic organ prolapse. Moreover, the companies are focusing on developing an extracellular matrix for soft tissue repair. For instance, in February 2020, Aroa Biosurgery launched Myriad, a new product for soft tissue repair and reconstruction, in the United States market. Myriad can be used for a variety of plastic and reconstructive surgical operations that require the repair or reinforcement of soft tissue, including plastic surgery, limb salvage, burns, and trauma.

However, the high cost of these extracellular matrix patch grafts has impeded the growth of the market.

Key Market Trends

Cardiac Repair is Expected to Have the Significant Market Share

The main factor driving the growth of the market is the increasing number of cardiovascular diseases. According to the National Center of Biotechnology Information, 2020, around 64.3 million people are suffering from heart failure worldwide. In addition, the prevalence rate of heart failure in the adult population is about 0.8% to 4.0%. According to the data published by Philippine Statistics Authority (PSA), 2020, it has been observed that ischaemic heart diseases were the leading cause of death from January to October 2021, with 110,332 cases or 18.3% of the total deaths in the country. Moreover, the number of children with congenital heart diseases has been increasing over the past year and thus leading to the adoption of these cardiovascular repair patches for diagnosing and driving the overall market.

The decentralized extracellular matrix patches are widely used in cardiac tissue repair. For instance, according to the National Center for Biotechnology Information, 2020, the rich array of proteins, glycosaminoglycans, proteoglycans, and many other matrix components found in natural tissue are most efficiently captured by decellularized extracellular matrix (dECM), offering perfect cues for regeneration and repair of injured myocardium. This makes dECM a promising biomaterial for repairing cardiovascular tissue.

North America is Expected to Have the Significant Market Share

North America is expected to witness a significant share of market growth in the forecast period. The factors propelling the growth of the market are the increasing incidence of cardiovascular diseases and defects, sports injuries, trauma cases, growing research and development expenditure, and increasing incidences of hernia disorders. According to the American Association for the Surgery of Trauma, 2021, trauma is the leading cause of death for individuals up to the age of 45 years. As per the same source, the annual toll of trauma in the United States is USD 4.2 trillion.

In addition, the rising geriatric population is also likely to boost the market growth as they are more prone to cardiovascular diseases. According to the Administration for Community Living report 2020, the number of Americans aged 65 and above was 16.9% of the total population in 2020, and it is estimated to about double to 94.7 million by 2060, and the 65-and-older age group’s share of the total population will rise from 16% to 21.6% in the United States. According to the Center for Disease Control and Prevention, Coronary heart disease is the most common type of heart disease, killing 360,900 people in 2019 in the United States.

Moreover, the United States spends a significant percentage of its GDP on healthcare each year. According to Organization for Economic Cooperation and Development, 2021, the United States has the greatest healthcare spending, sitting at USD 10,224 per capita.

Competitive Landscape

The global extracellular matrix patches market is highly competitive with the presence of major players. The major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, and acquisitions to increase their footprints in this market. Some of the key players are Baxter International, Coloplast, MTF Biologics, Terumo Corporation, and Aziyo Biologics.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Number of Surgeries
4.2.2 Adoption of Extracellular Matrix Patch in Hernia and Pelvic Reconstruction Surgeries
4.3 Market Restraints
4.3.1 High Cost of Extracellular Matrix Patch Procedure
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Raw Material
5.1.1 Porcine
5.1.2 Bovine
5.1.3 Others
5.2 By Application
5.2.1 Soft Tissue Repair
5.2.2 Cardiac Repair
5.2.3 Vascular Repair & Reconstruction
5.2.4 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Baxter International
6.1.2 Becton, Dickinson, and Company
6.1.3 Terumo Corporation
6.1.4 LeMaitre
6.1.5 Smith+Nephew
6.1.6 Aziyo Biologics
6.1.7 Integra LifeSciences Corporation
6.1.8 Coloplast
6.1.9 Medtronic
6.1.10 MTF Biologics
6.1.11 Koninklijke DSM N.V.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Baxter International
  • Becton, Dickinson, and Company
  • Terumo Corporation
  • LeMaitre
  • Smith+Nephew
  • Aziyo Biologics
  • Integra LifeSciences Corporation
  • Coloplast
  • Medtronic
  • MTF Biologics
  • Koninklijke DSM N.V.